Compounding Drugs Safety Act

Summary#

The SAFE Drugs Act of 2026 would change how some compounding pharmacies, outsourcing facilities, and physicians that compound drugs are regulated under the Federal Food, Drug, and Cosmetic Act. Its main goals are to limit routine compounding of copies of commercially available drugs, add reporting for out-of-state compounding, require more inspections of larger outsourcing facilities, and let the agency set a base establishment fee to fund safety work.

• Limits routine compounding of a drug that is “essentially a copy” of a commercially available product to no more than 20 times in a single month.
• Adds a yearly reporting requirement for any pharmacy, facility, or physician that compounds a drug (that contains an active ingredient found in a commercially available product) more than 20 times in a month for patients who live outside the State where the compounding occurs. Hospital on‑premises pharmacy compounding for hospital patients is excluded from the reporting rule.
• Defines “large-scale outsourcing facility” as an outsourcing facility that compounds any drug product more than 100 times in a calendar year and requires an inspection before it first compounds and at least every two years thereafter. These provisions start six months after enactment.
• Removes an existing registration exemption for outsourcing facilities in a specified paragraph (so those facilities would no longer be covered by that exemption).
• Replaces a fixed $15,000 base establishment fee with a base amount set by the Secretary (the agency head) to fund safety activities for compounded drug products.

What it means for you#

• Compounding pharmacies and physician-compounders

  • Must avoid routinely making copies of commercially available drugs more than 20 times in a month if they want to meet the bill’s standard.
  • Must report annually if they compounded such products more than 20 times in a month for patients who live in another State. Reports must list drug types and monthly counts and be filed by the end of the calendar year in the form the Secretary requires.
  • Could face more oversight if they operate at the higher activity levels defined in the bill.

• Outsourcing facilities

  • Those that compound a given drug product more than 100 times in a year are treated as “large-scale” and must be inspected before first compounding and at least every two years afterward.
  • Will lose the specific registration exemption referenced in the bill text (meaning additional registration or regulatory steps may be required).

• Hospitals

  • On‑premises hospital pharmacies compounding for hospital patients are excluded from the new reporting requirement.

• Patients

  • This could change access to certain compounded medicines if pharmacies reduce how often they compound copies of commercially available drugs to stay under the numeric limits. The bill does not say how clinical decisions about individual patient needs will be enforced.

• The federal agency (Secretary)

  • Gains authority to set the base establishment fee amount to fund safety activities and to prescribe the form and manner of the new reports.

Expenses#

No publicly available information.

• The bill does not include a fiscal note in the provided material.
• Likely areas of cost (not estimated here) include: FDA inspection and enforcement costs; administrative costs for pharmacies, physicians, and outsourcing facilities to prepare and submit reports; potential fee revenue or higher fees set by the Secretary to fund safety activities; and compliance costs for facilities that must newly register or undergo inspection.
• The bill gives the Secretary discretion to set the base fee amount, but it does not specify an amount or a timetable for fee changes.

Proponents' View#

• The bill appears intended to reduce routine large‑scale compounding of products that duplicate commercially available drugs, which could be seen as protecting patients from unsafe or unverified versions of those drugs.
• The reporting rule and inspections for larger facilities could improve transparency about how often compounding occurs across State lines and increase regulatory oversight of higher‑volume operations.
• Allowing the Secretary to set the base fee could give the agency flexibility to fund activities needed to monitor and inspect compounding operations.

Opponents' View#

• One concern is that the numeric limits (20 times per month; 100 times per year) may be arbitrary and could reduce patient access to needed compounded medicines without clear clinical justification.
• The bill does not clearly explain enforcement actions or penalties for exceeding the limits. It is unclear how regulators would handle close calls or clinically justified repeat compounding.
• The phrase “significant difference, as determined by the prescribing practitioner” is subjective and may create inconsistent outcomes across prescribers.
• The Secretary’s discretion to set the base fee could lead to higher or unpredictable fees for establishments; the bill does not set limits or transparency requirements on how the fee is calculated.
• The fiscal impact on FDA (for more inspections and report processing) and on compounding pharmacies (for compliance and reporting) is not estimated in the provided material.